MARATTO

article · Bulletin of Faculty of Science Zagazig University

Synthesis, characterization, and antimicrobial evaluation of some novel Imidazo[1,2-c] pyrimidine derivatives

20241 citationZagazig University

Abstract

Due to chalcone compounds' diverse and intriguing bioactive characteristics, the present work recommends the production of several new chalcone derivatives, followed by spectral characterization utilizing various spectral techniques such as IR, NMR, and elemental analyses. In addition to, assessment the antimicrobial activity of imidazo[1,2-c] pyrimidine derivatives. All tested new chalcone compounds showed antibacterial activity against P. aeruginosa and B. subtilis, while only compounds (5a-d and 5f) displayed activity against E. coli. Furthermore, only compounds (5a-c, 5e and 5f) reduced the development of S. aureus. The compound 5f revealed significant antibacterial activity against S. aureus (87.5%), B. subtilis (82.61 %), P. aeruginosa (78.26%) and E. coli (64%), when compared to Ampicillin. On the other hand, the compounds (5a-d, 5e and 5f) showed antifungal activity against C. Albicans. Also, compounds (5a, 5b, 5c, 5d and 5f) displayed activity against A. flavus. A significant antifungal activity for compound 5b has been observed against C. Albicans (70.37%) and A. flavus (52%), when compared to Colitrima-zole.

Research topics

  • Synthesis and biological activity
  • Synthesis and Characterization of Heterocyclic Compounds
  • Multicomponent Synthesis of Heterocycles

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

DOI: 10.21608/bfszu.2024.267543.1363

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.